Synergistic Effect Of Administration Of Nutraceuticals In Polycystic Ovarian Syndrome In Tertiary Care Hospital

Abstract

Polycystic Ovary Syndrome (PCOS) is an endocrine disorder in women of childbearing age, present in approximately one-third of women in the reproductive age group. Hormonal disorders, metabolic complications, and ovulatory disorders manifest themselves. Because conventional treatments may have side effects and their efficacy ranges from good to poor, there is a growing interest in nutraceuticals as additional therapy. The rationale for this study is to assess the clinical combined interaction of some chosen nutraceuticals which have been reported to work on hormonal balance and metabolism of women with PCOS, such as myoinositol, D chiro inositols, omega three fatty acids, and vitamins and minerals.

Female subjects aged 18-40 years presenting to the outpatient clinic with Rotterdam criteria defining PCOS will be recruited prospectively in this trial. After six months, participants will have been randomized to either receive the blend of nutraceuticals or a placebo. Fertility (ovulation rates and fertility status) and metabolic (fetal growth and insulin sensitivity) outcomes will be positively correlated with hormonal (testosterone, LH, and FSH) outcomes, which will help elucidate the role of testosterone signalling in each outcome.

The nutraceutical interventions are anticipated to demonstrate highly significant changes in all hormonal parameters and general metabolic conditions of the intervention group compared to the control group. More particularly, testosterone levels are expected to decline, insulin sensitivity to improve, and ovulation rates to increase. Such findings also establish the possibility of using nutraceuticals to enhance the outcomes of conventional approaches to managing PCOS adequately.